NX1 Price sensitive 31 Jul 2026, 1:07 PM

Jun26 Appendix 4C Cash Flow Report

Nexalis Therapeutics Ltd

NX1.ASX Announces Quarterly Cash Flow Report

Key points

  • Current quarter net cash from operating activities: $648,000
  • Year-to-date net cash from operating activities: $174,000
  • No unused financing facilities available at quarter end

Full summary

NX1.ASX has released its quarterly cash flow report for the quarter ended 30 June 2026, detailing cash flow activities and financing. The company reported net cash from operating activities of $648,000 for the current quarter and $174,000 year-to-date. Investing activities resulted in a net cash outflow of $16,000 for the quarter and $16,000 year-to-date. Financing activities showed a net cash inflow of $323,000 for the quarter and $196,000 year-to-date. The company had no unused financing facilities available at the end of the quarter.

Outlook

NX1.ASX continues to assess alternative funding options for its clinical development programs, with no meaningful discussions underway with a replacement funding partner.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in